Key points from article :
Novartis and IBM Watson will create a cognitive platform for breast cancer.
Will use real-world data to better predict treatment effects on patients.
Watson can reduce time required to screen patients for clinical trials by 78%.
Previous study showed >90% concordance rate with human treatment recommendations.
Lower for some cancers, particularly when guidelines different to where Watson was trained.
